Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetic study of FcγRIIIa and HER2 genes in relation to trastuzumab treatment of breast cancer
2006-002532-24Phase 4Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of trastuzumab in breast cancer, sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoints: Frequency of HER2 gene polymorphisms and association with HER2 receptor expression and Frequency of FcγRIIIa and related gene polymorphisms and association with response to trastuzumab. Started Apr 2007; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-002532-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002532-24.